These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16224447)

  • 21. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group.
    Manetta A; Blessing JA; Hurteau JA
    Gynecol Oncol; 1998 Jan; 68(1):45-6. PubMed ID: 9454659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association of taxane resistance genes with the clinical course of ovarian carcinoma.
    Ehrlichova M; Mohelnikova-Duchonova B; Hrdy J; Brynychova V; Mrhalova M; Kodet R; Rob L; Pluta M; Gut I; Soucek P; Vaclavikova R
    Genomics; 2013 Aug; 102(2):96-101. PubMed ID: 23542236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy].
    Kawashima T; Murakami H; Kanamori T; Nakamura Y
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):461-3. PubMed ID: 17353644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.
    Ferriss JS; Kim Y; Duska L; Birrer M; Levine DA; Moskaluk C; Theodorescu D; Lee JK
    PLoS One; 2012; 7(2):e30550. PubMed ID: 22348014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy.
    Kurzeder C; Sauer G; Deissler H
    Curr Cancer Drug Targets; 2006 May; 6(3):207-27. PubMed ID: 16712458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage therapy for recurrent epithelial ovarian cancer.
    Baker VV
    Hematol Oncol Clin North Am; 2003 Aug; 17(4):977-88. PubMed ID: 12959187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer.
    Case AS; Rocconi RP; Partridge EE; Straughn JM
    Gynecol Oncol; 2007 Apr; 105(1):223-7. PubMed ID: 17215031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salvage treatment with docetaxel for recurrent epithelial ovarian cancer.
    Niwa Y; Nakanishi T; Kuzuya K; Nawa A; Mizutani S
    Int J Clin Oncol; 2003 Dec; 8(6):343-7. PubMed ID: 14663634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrent ovarian carcinoma: salvage treatment with platinum in patients responding to first-line platinum-based regimens.
    Chiara S; Campora E; Merlini L; Simoni C; Iskra L; Odicino F; Ragni N; Conte PF; Rosso R
    Eur J Cancer; 1993; 29A(4):652. PubMed ID: 8435226
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
    Lin H; Changchien CC
    Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
    Gronlund B; Engelholm SA; Horvath G; Mäenpää J; Ridderheim M
    Cancer; 2005 Apr; 103(7):1388-96. PubMed ID: 15719439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
    Goldberg JM; Piver MS; Hempling RE; Recio FO
    Gynecol Oncol; 1996 Dec; 63(3):312-7. PubMed ID: 8946864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
    Wolf JK; Bodurka DC; Verschraegen C; Sun CC; Branham D; Jenkins AD; Atkinson N; Gershenson DM
    Gynecol Oncol; 2006 Sep; 102(3):468-74. PubMed ID: 16516276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel in the management of ovarian cancer.
    Blagden SP; Kaye SB
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):203-14. PubMed ID: 15877518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
    Matsuo K; Bond VK; Im DD; Rosenshein NB
    Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug evaluation: Bay-59-8862.
    Eckstein JW
    IDrugs; 2004 Jun; 7(6):575-81. PubMed ID: 15197663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent ovarian carcinoma: diagnosis and second-line therapy.
    Geary M; Foley M; Lenehan P; Murphy J; Fennelly J
    Ir Med J; 1995; 88(2):68-70. PubMed ID: 7775151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
    Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.